dual Mcl-1 and Bcl-xL inhibitors (Takeda Pharmaceuticals)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual Mcl-1 and Bcl-xL inhibitors (Takeda Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitorsApoptosis regulator Bcl-X inhibitors
TargetsInduced myeloid leukemia cell differentiation protein Mcl-1Apoptosis regulator Bcl-X
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A